Leishmania chagasi T-cell antigens identified through a double library screen

Infection and Immunity

Volumn 74, Issue 12, 2006, Pages 6940-6948

  Martins, Daniella R A ^a   Jeronimo, Selma M B ^a   Donelson, John E ^b   Wilson, Mary E ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; B LYMPHOCYTE ANTIGEN; ELONGATION FACTOR; ELONGATION FACTOR 1GAMMA; EPITOPE; GAMMA INTERFERON; GLUTAMATE AMMONIA LIGASE; HEAT SHOCK PROTEIN; KINESIN; KINESIN K39; POLYPEPTIDE; REPETITIVE PROTEIN A2; T LYMPHOCYTE ANTIGEN;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; BRAZIL; CELLULAR IMMUNITY; CLONE; CONTROLLED STUDY; DNA LIBRARY; ENDEMIC DISEASE; ENDOPLASMIC RETICULUM; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; LEISHMANIA CHAGASI; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SERODIAGNOSIS; SOUTH AMERICA; VERTEBRATE; VISCERAL LEISHMANIASIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BLOTTING, NORTHERN; DNA, COMPLEMENTARY; EPITOPES, T-LYMPHOCYTE; GENE LIBRARY; HUMANS; IMMUNE SERA; LEISHMANIA; MICE; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS;

EID: 33845501839     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.02032-05     Document Type: Article

References (61)

1. Armijos, R. X., M. M. Weigel, M. Calvopina, A. Hidalgo, W. Cevallos, and J. Correa. 2004. Safety, immunogenicity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 22:1320-1326.
2. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.). 2006. Current protocols in molecular biology. John Wiley & Sons, Inc., New York, N.Y.
3. Beetham, J. K., K. S. Myung, J. J. McCoy, M. E. Wilson, and J. E. Donelson. 1997. Glycoprotein 46 mRNA abundance is post-transcript ionally regulated during development of Leishmania chagasi promastigotes to an infectious form. J. Biol. Chem. 28:17360-17366.
4. Berens, R. L., R. Brun, and S. M. Krassner. 1976. A simple monophasic medium for axenic culture of hemoflagellates. J. Parasitol. 62:360-365.
5. Braz, R. F. S., E. T. Nascimento, D. R. A. Martins, M. E. Wilson, R. D. Pearson, S. G. Reed, and S. M. B. Jeronimo. 2002. The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection. Am. J. Trop. Med. Hyg. 67:344-348.
6. Burns, J. M., Jr., W. G. Shreffler, D. R. Benson, H. W. Ghalib, R. Badaro, and S. G. Reed. 1993. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc. Natl. Acad. Sci. USA 90:775-779.
7. Campbell, K., H. Diao, J. Ji, and L. Soong. 2003. DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous leishmaniasis. Infect. Immun. 71:6270-6278.
8. Campbell, K., V. Popov, and L. Soong. 2004. Identification and molecular characterization of a gene encoding a protective Leishmania amazonensis Trp-Asp (WD) protein. Infect. Immun. 72:2194-2202.
9. Campos-Neto, A., R. Perrozzi, and K. Greeson. 2001. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect. Immun. 69:4103-4108.
10. Campos-Neto, A., L. Soong, J. L. Cordova, D. Sant'Angelo, Y. A. W. Skeiky, N. H. Ruddle, S. G. Reed, C. Janeway, and D. McMahon-Pratt. 1995. Cloning and expression of an Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages. J. Exp. Med. 182:1423-1433.
11. Canavate, C., M. el Bali, Y. Montoya, D. C. Barker, and J. Alvar. 2002. Isolation and characterization of Leishmania infantum cDNA encoding a protein homologous to eukaryotic elongation factor 1 gamma. Trans. R. Soc. Trop. Med. Hyg. 96:S41-S47.
12. Carvalho, L. P., M. Soto, S. M. B. Jeronimo, B. Dondji, C. Alonso, A. Ribeiro de Jesus, and E. M. Carvalho. 2003. Characterization of the immune response to Leishmania infantum recombinant antigens. Microbes Infect. 5:7-12.
13. Champsi, J., and D. McMahon-Pratt. 1988. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 52:3272-3279.
14. Charest, H., and G. Matlashewski. 1994. Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene. Mol. Cell. Biol. 14:2975-2984.
15. Chomczynski, P., and N. Sacchi. 1987. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
16. Coligan, J. E., A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober. 1991. Current protocols in immunology. John Wiley and Sons, New York, N.Y.
17. Costa, C. H., H. F. Pereira, and M. V. Araujo. 1990. Epidemia de leishmaniose visceral no estado do Piaui, Brasil. Rev. Saude Publica 24:361-372.
18. Coulson, R. M. R., and D. F. Smith. 1990. Isolation of genes showing increased or unique expression in the infective promastigotes of Leishmania major. Mol. Biochem. Parasitol. 40:63-76.
19. Davies, C. R., P. M. Kaye, S. L. Croft, and S. Sundar. 2003. Leishmaniasis: new approaches to disease control. BMJ 326:377-382.
20. De Andrade, C. R., L. V. Kirchhoff, J. E. Donelson, and K. Otsu. 1992. Recombinant Leishmania Hsp90 and Hsp70 are recognized by sera from visceral leishmaniasis patients but not Chagas' disease patients. J. Clin. Microbiol. 30:330-335.
21. Evans, T. G., M. J. Teixeira, I. T. McAuliffe, I. De Alencar Barros Vasconcelos, A. Wilson Vasconcelos, A. De Queiroz Sousa, J. Wellington de Oliveira Limaqq, and R. D. Pearson. 1992. Epidemiology of visceral leishmaniasis in northeast Brazil. J. Infect. Dis. 166:1124-1132.
22. Galvao-Castro, B., J. A. S. A. Ferreira, M. C. Marzochi, S. G. Marzochi, S. G. Continho, and P. H. Lambert. 1984. Polyclonal B cell activation, circulating immune complexes and autoimmunity in human American visceral leishmaniasis. Clin. Exp. Immunol. 56:58-66.
23. Ghedin, E., W.-W. Zhang, H. Charest, S. Sundar, R. T. Kenney, and G. Matlashewski. 2005. Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin. Diagn. Lab. Immunol. 4:530-535.
24. Ghosh, A., S. Labrecque, and G. Matlashewski. 2001. Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 19:3169-3178.
25. Ghosh, A., W. W. Zhang, and G. Matlashewski. 2001. Immunization with A2 protein results in mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infection. Vaccine 20:59-66.
26. Ghosh, M., and S. Bandyopadhyay. 2003. Present status of antileishmanial vaccines. Mol. Cell Biochem. 253:199-205.
27. Goyard, S., H. Segawa, J. Gordon, M. Showalter, R. Duncan, S. J. Turco, and S. M. Beverley. 2003. An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans. Mol. Biochem. Parasitol. 130:31-42.
28. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 2005. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137-1147.
29. Handman, E., A. H. Noormohammadi, J. M. Curtis, T. Baldwin, and A. Sjolander. 2000. Therapy of murine cutaneous leishmaniasis by DNA vaccination. Vaccine 18:3011-3017.
30. Herwaldt, B. L. 1999. Leishmaniasis. Lancet 354:1191-1199.
31. Jeronimo, S. M. B., P. Duggal, R. F. S. Braz, C. Cheng, G. R. G. Monteiro, E. T. Nascimento, F. L. Bezerra, T. M. Karplus, M. F. F. M. Ximenes, C. G. C. Oliveira, V. G. Pinheiro, D. R. A. Martins, J. M. Peralta, J. M. Sousa, I. M. Medeiros, R. D. Pearson, T. L. Burns, E. W. Pugh, and M. E. Wilson. 2004. An emerging peri-urban pattern of infection with Leishmania chagasi, the protozoan causing visceral leishmaniasis in northeast Brazil. Scand. J. Infect. Dis. 36:443-449.
32. Kaye, P. M. 2002. The immunology of visceral leishmaniasis: current status, p. 137-150. In J. P. Farrell (ed.), Leishmania, vol. 4. Kluwer Academic Publishers, Boston, Mass.
33. MacBeath, J. R. E., S. S. Harvey, and N. J. Oldroyd. 2001. Automated fluorescent DNA sequencing on the ABI PRISM 377, p. 119-152. In C. A. Graham and A. J. M. Hill (ed.), DNA sequencing protocols, vol. 167. Humana Press, Inc., Totowa, N.J.
34. Mauel, J. 2002. Vaccination against Leishmania infections. Curr. Drug Targets Immune Endocr. Metab. Disord. 2:201-226.
35. Mauricio, I. L., J. R. Stothard, and M. A. Miles. 2000. The strange case of Leishmania chagasi. Parasitol. Today 16:188-189.
36. McKean, P. G., P. W. Denny, E. Knuepfer, J. K. Keen, and D. F. Smith. 2001. Phenotypic changes associated with deletion and overexpression of a stage-regulated gene family in Leishmania. Cell. Microbiol. 3:511-523.
37. Means, T. K., D. T. Golenbock, and M. J. Fenton. 2000. The biology of Toll-like receptors. Cytokine Growth Factor Rev. 11:219-232.
38. Melby, P. C., J. Yang, W. Zhao, L. E. Perez, and J. Cheng. 2001. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69:4719-4725.
39. Momen, H., R. S. Pcheco, E. Cupolillo, and G. Grimaldi. 1993. Molecular evidence for the importation of Old World Leishmania into the Americas. Biol. Res. 26:249-255.
40. Mustafa, A. S., F. Oftung, A. Deggerdal, H. K. Gill, R. A. Young, and T. Godal. 1988. Gene isolation with human T lymphocyte probes. Isolation of a gene that expresses an epitope recognized by T cells specific for Mycobacterium bovis BCG and pathogenic mycobacteria. J. Immunol. 141:2729-2733.
41. Nandan, D., T. Yi, M. Lopez, C. Lai, and N. E. Reiner. 2002. Leishmania EF-1α activates the Src homology 2 domain containing tyrosine phosphatase SHP-1 leading to macrophage deactivation. J. Biol. Chem. 277:50190-50197.
42. Pearson, R. D., and A. Q. Sousa. 1996. Clinical spectrum of leishmaniasis. Clin. Infect. Dis. 22:1-13.
43. Rachamin, N., and C. L. Jaffe. 1999. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150:2322-2331.
44. Rafati, S., A. A. Baba, M. Bakhshayesh, and M. Vafa. 2000. Vaccination of Balb/c mice with Leishmania major amastigote-specific cysteine proteinase. Clin. Exp. Immunol. 120:134-138.
45. Reed, S. G., R. Badaro, H. Masur, E. M. Carvalho, R. Lorenco, A. Lisboa, R. Teixeira, W. D. Johnson, and T. C. Jones. 1986. Selection of a skin test antigen for American visceral leishmaniasis. Am. J. Trop. Med. Hyg. 35:79-85.
46. Reed, S. G., and A. Campos-Neto. 2003. Vaccines for parasitic and bacterial diseases. Curr. Opin. Immunol. 15:456-460.
47. Singh, N., R. T. Singh, and S. Sundar. 2003. Novel mechanism of drug resistance in kala-azar field isolates. J. Infect. Dis. 188:600-607.
48. Skeiky, Y. A. W., M. Kennedy, D. Kaufman, M. M. Borges, J. A. Guderian, J. K. Scholler, P. J. Ovendale, K. S. Picha, P. J. Morrissey, K. H. Grabstein, A. Campos-Neto, and S. G. Reed. 1998. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol. 161:6171-6179.
49. Soong, L., S. M. Duboise, P. Kima, and D. McMahon-Pratt. 1995. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect. Immun. 63:3559-3566.
50. Stager, S., D. F. Smith, and P. M. Kaye. 2000. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 165:7064-7071.
51. Streit, J. A., T. J. Recker, F. G. Filho, S. M. Beverley, and M. E. Wilson. 2001. Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms. J. Immunol. 166:1921-1929.
52. Sundar, S. 2001. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 6:849-854.
53. n gene: in vivo evidence for a dominant negative mutation. J. Immunol. 162:5666-5670.
54. Walker, P. S., T. Scharton-Kersten, E. D. Rowton, U. Hengge, A. Bouloc, M. C. Udey, and J. C. Vogel. 1998. Genetic immunization with glycoprotein 63 cDNA results in helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum. Gene Ther. 9:1899-1907.
55. Wilson, M. E., K. A. Andersen, and B. E. Britigan. 1994. Response of Leishmania promastigotes to oxidant stress. Infect. Immun. 62:5133-5141.
56. Wilson, M. E., K. K. Hardin, and J. E. Donelson. 1989. Expression of the major surface glycoprotein of Leishmania donovani chagasi in virulent and attenuated promastigotes. J. Immunol. 143:678-684.
57. Wilson, M. E., S. M. B. Jeronimo, and R. D. Pearson. 2005. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb. Pathog. 38:147-160.
58. Wilson, M. E., and R. D. Pearson. 1986. Evidence that Leishmania donovani utilizes a mannose receptor on human mononuclear phagocytes to establish intracellular parasitism. J. Immunol. 136:4681-4688.
59. Wilson, M. E., B. M. Young, K. P. Andersen, J. V. Weinstock, A. Metwali, K. M. Ali, and J. E. Donelson. 1995. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect. Immun. 63:2062-2069.
60. Zhang, W. W., and G. Matlashewski. 1996. The developmental expression of Leishmania donovani A2 amastigote-specific genes is post-transcriptionally mediated and involves elements located in the 3′-untranslated region. J. Biol. Chem. 271:17081-17090.
61. Zhang, W.-W., H. Charest, E. Ghedin, and G. Matlashewski. 1996. Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani. Mol. Biochem. Parasitol. 78:79-90.